Syndax Pharmaceuticals Delnica

Syndax Pharmaceuticals Dividenda 2024

Syndax Pharmaceuticals Dividenda

0 USD

Syndax Pharmaceuticals Donosnost dividend

Simbol

SNDX

ISIN

US87164F1057

WKN

A2AFL6

Koliko dividende izplača Syndax Pharmaceuticals 2024?

Po trenutnih podatkih z dne december 2024 je Syndax Pharmaceuticals v zadnjih 12 mesecih izplačal skupno dividendo v višini 0 USD na delnico. Pri trenutnem Syndax Pharmaceuticals tečaju 13,31 USD to ustreza donosnosti dividende 0 %. Dividenda se izplača krat na leto.

=

Zgodovinske Syndax Pharmaceuticals dividende

Vsako leto se dividend izplača krat. Zadnje leto so bili meseci izplačil in .

Dan izplačilaDividenda

Je Syndax Pharmaceuticals dividenda varna?

Syndax Pharmaceuticals povečuje dividendo že 0 let.

V zadnjih 10 letih je Syndax Pharmaceuticals to vrednost povečal za 0 % letno.

V petletnem obdobju se je izplačilo povečalo za 0 %.

Analitiki za tekoče poslovno leto pričakujejo rast Znižanje dividend za −100,000%.

Podrobnosti o dividendah

Razumevanje dividendnih izplačil od Syndax Pharmaceuticals

Dividende od Syndax Pharmaceuticals so del dobička podjetja, ki se izplača delničarjem. So ključen kazalec finančnega zdravja podjetja in privlačnosti za vlagatelje. Dividende vlagateljem nudijo stalni vir dohodka, poleg dobičkov, ki se lahko pridobijo s prodajo delnice po višji ceni od nakupne.

Primerjava iz leta v leto

Proučevanje dividendnih izplačil od Syndax Pharmaceuticals čez leta lahko izpostavi donosnost in stabilnost podjetja. Konstantna ali naraščajoča dividendna izplačila lahko kažejo na finančno zdravo podjetje s predvidljivimi dobički, medtem ko lahko nihanje ali znižanja dividend nakazujejo na obstoječe finančne ali operativne izzive.

Vplivi na investicije

Izplačila dividend od Syndax Pharmaceuticals so ključni dejavnik za vlagatelje, ki so usmerjeni na dohodek. Močno izplačilo dividend lahko poveča privlačnost delnice in zagotovi redni dohodek poleg morebitnih kapitalskih dobičkov. Lahko tudi pokaže zaupanje podjetja v svoje prihodnje dobičke in je tako pomemben dejavnik pri odločitvah o naložbah.

Interpretacija nihanj dividend

Spremembe v dividendah od Syndax Pharmaceuticals lahko nastopijo zaradi sprememb v dobičkih podjetja, finančni politiki ali strategijah reinvestiranja. Povečanje dividend pogosto signalizira finančno stabilnost, medtem ko znižanje lahko nakazuje na potrebo po ohranjanju denarnih sredstev ali reinvestiranju dobičkov za spodbujanje rasti, pri čemer ima vsak scenarij različne posledice za vlagatelje.

Syndax Pharmaceuticals Aktienanalyse

Kaj počne Syndax Pharmaceuticals?

Syndax Pharmaceuticals Inc. is a biotechnology company based in Waltham, Massachusetts that focuses on the development of novel therapeutics for cancer and immune disorders. The company was founded in 2005 by Arlene Morris and has been listed on NASDAQ since 2014. Business model and product pipeline: Syndax develops small molecules that are capable of modulating epigenetic changes in cells. This approach is based on the understanding that cancer cells often have genetic alterations that result in changes in gene expression. By modulating such epigenetic changes, cancer cells can function normally again, which can help stop or inhibit the growth of cancer cells. The company's product pipeline includes several drugs that are being developed in various stages of clinical research. One of the most advanced programs is E2112, an orally administered drug targeting breast cancer. The drug is currently in Phase III studies that are investigating the efficacy and safety of the drug in combination with other standard therapies. Another promising program is SNDX-6352, an anti-CSF-1 receptor antibody being developed for the treatment of various types of cancer, including certain solid tumors and hematologic malignancies. The drug has been successfully tested in Phase Ib studies, and the company is currently planning to evaluate it in further clinical trials. In addition to cancer research, Syndax is also working on the development of therapeutics for various inflammatory and immunologic diseases. The company is working on a program for the treatment of idiopathic pulmonary fibrosis and also a program for the treatment of thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. In addition to internally developed drugs, the company is collaborating with other biotechnology and pharmaceutical companies to explore innovative treatment options for other diseases. The company has entered into a partnership with Japanese company Kyowa Hakko Kirin Co. Ltd. to develop and market the SNDX-6352 program. Current developments: Syndax has recently experienced strong growth and is investing significantly in research and development to expand its pipeline and expand its drugs. The company recently completed a financing round that raised $80 million to advance its development projects. A key milestone for the company was the appointment of Briggs W. Morrison as CEO in 2020. Morrison, an experienced pharmaceutical manager, was previously the Chief Executive Officer and President of Syndax until 2016. He is now returning to the company and leading efforts to develop innovative therapeutics. Morrison has previously worked at Pfizer and AstraZeneca, bringing valuable experience in the development and marketing of new drugs. Summary: Syndax Pharmaceuticals Inc. is a biotechnology company that focuses on the development of drugs for cancer and inflammatory diseases. The company has a promising product pipeline that includes several therapeutics in various stages of development, including E2112 and SNDX-6352. Syndax recently completed a strong financing round and plans to continue its research and development efforts to discover and develop new innovative therapeutics. Syndax Pharmaceuticals je eno izmed najbolj priljubljenih podjetij na Eulerpool.com.
Delniški varčevalni načrti ponujajo privlačno možnost za vlagatelje, da dolgoročno zgradijo premoženje. Eden glavnih prednosti je tako imenovani učinek povprečenja stroškov: Z rednim vlaganjem fiksnega zneska v delnice ali delniške sklade se avtomatsko kupi več enot, ko so cene nizke, in manj, ko so visoke. To lahko vodi do ugodnejše povprečne cene na enoto s časom. Poleg tega delniški varčevalni načrti omogočajo tudi malim vlagateljem dostop do dragih delnic, saj se lahko pridružijo že z majhnimi zneski. Redna investicija tudi spodbuja disciplinirano investicijsko strategijo in pomaga izogibati se čustvenim odločitvam, kot so impulzivno kupovanje ali prodaja. Poleg tega vlagatelji profitirajo od potencialne rasti vrednosti delnic kot tudi od izplačil dividend, ki se lahko reinvestirajo, kar povečuje učinek obrestnega obrestovanja in s tem rast investiranega kapitala.

Delnica Syndax Pharmaceuticals je primerna za varčevalne načrte pri naslednjih ponudnikih: Trade Republic

Pogosta vprašanja o delnici Syndax Pharmaceuticals

Koliko dividende izplača Syndax Pharmaceuticals?

V zadnjih 12 mesecih je Syndax Pharmaceuticals izplačal dividendo v višini . To ustreza približni donosnosti dividend . V prihajajočih 12 mesecih bo Syndax Pharmaceuticals predvidoma izplačal dividendo v višini 0 USD.

Kakšen je donos dividend od Syndax Pharmaceuticals?

Trenutni donos od dividend za Syndax Pharmaceuticals znaša .

Kdaj Syndax Pharmaceuticals izplača dividend?

Syndax Pharmaceuticals izplačuje četrtletno dividendo. Ta se izplačuje v mesecih .

Kako varna je dividenda od Syndax Pharmaceuticals?

Syndax Pharmaceuticals je v zadnjih 0 letih vsako leto izplačeval dividend.

Kakšna je dividenda od Syndax Pharmaceuticals?

V naslednjih 12 mesecih se pričakuje dividende v višini 0 USD. To ustreza dividendnemu donosu 0 %.

V katerem sektorju se nahaja Syndax Pharmaceuticals?

Syndax Pharmaceuticals je razvrščen v sektor 'Zdravje'.

Wann musste ich die Aktien von Syndax Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

Da si prejel zadnjo dividendo Syndax Pharmaceuticals z dne 24. 12. 2024 v višini 0 USD, si moral imeti delnico v depoju pred dnevom brez pravice do dividende (Ex-Tag) 24. 12. 2024.

Kdaj je Syndax Pharmaceuticals izplačal zadnjo dividendo?

Zadnje izplačilo dividende je bilo 24. 12. 2024.

Kakšna je bila dividenda od Syndax Pharmaceuticals v letu 2023?

V letu 2023 je Syndax Pharmaceuticals 0 USD izplačal kot dividende.

V kateri valuti Syndax Pharmaceuticals izplača dividendo?

Dividende od Syndax Pharmaceuticals se izplačujejo v USD.

Andere Kennzahlen von Syndax Pharmaceuticals

Naša analiza delnic Syndax Pharmaceuticals Prihodki vključuje pomembne finančne kazalnike, kot so prihodki, dobiček, razmerje cena/dobiček (KGV), razmerje cena/prihodki (KUV), EBIT ter informacije o dividendah. Prav tako preučujemo aspekte, kot so delnice, tržna kapitalizacija, dolgovi, lastniški kapital in obveznosti Syndax Pharmaceuticals Prihodki. Če iščete podrobnejše informacije o teh temah, na naših podstraneh nudimo obsežne analize: